Catherine Skari

Chinese Base Editing Therapy ‘Clinically Cured’ Patient with β-Thalassaemia, Researchers Say

Shanghai-based biotech company CorrectSequence Therapeutics, in collaboration with Guangxi Medical University, has achieved a significant clinical milestone by successfully treating…

Read More »

COLD AGGLUTININ DISEASE | ANX1502 Passes Phase 1 Trial, Proving Safe for Healthy Volunteers

Administered orally as a liquid suspension, ANX1502 demonstrated good tolerability, with no serious side effects reported. The drug’s pharmacokinetics also…

Read More »

TIF Newsletter – December 2023

 

Read More »

A YEAR IN RETROSPECT | Global Public Health Achievements and Challenges in 2023

We applaud the remarkable strides in eradicating diseases and infections, such as ending the COVID-19 public health emergency and intensifying…

Read More »

wAIHA | Fostamatinib May Induce Durable Hemoglobin Response in Subset of Patients

Interestingly, this positive outcome was predominantly observed among participants hailing from North America, Australia, or Western Europe, while those from…

Read More »

SICKLE CELL DISEASE | FDA Approves Two Landmark Gene Therapies for the Treatment of the Disorder

The two therapies are Casgevy (exa-cel) by Vertex Pharmaceuticals and CRISPR Therapeutics – the world’s first drug to utilize the…

Read More »

NEWS | ICER Releases Draft Evidence Report on Treatment for Paroxysmal Nocturnal Hemoglobinuria

This preliminary draft marks the midpoint of ICER’s eight-month process of assessing these treatments, and the findings within this document…

Read More »

PHARMA NEWS | FDA Approves Iptacopan for Paroxysmal Nocturnal Hemoglobinuria

Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive…

Read More »

NEW WEBINAR | Empowering Patient Leaders: Understanding EU Health Policies

📌 Webinar Title: ‘‘Empowering Patient Leaders: Understanding EU Health Policies’’ 📌 Date & Time: 18 December 2023, Monday, at 14:00…

Read More »